

TEACHING IMPROVEMENT
SCIENCE (TIS):
WEEK 6



Today's Agenda


- **Recap week 5**
- System vs cognitive errors
- Cognitive bias
- Wrap up
- HSPs



MODIFIED A3		Develop Countermeasures:
Background:	Root Causes:	
Current State:	Targets & Metrics:	Implement Countermeasures (PDSA):
		Follow Up Plan:


Ways to display data:

Histogram




- *Depicts the distribution of a set of data*
- *Use it to see where the majority of values fall*

Pareto of interruptions by minutes





- *A sorted bar graph*
- *Use it when there are many problems or causes and you want to focus on the most significant*

Run chart




- *A line graph of data plotted over time.*
- *Use it to study observed data for trends or patterns over a specified period*


QI Project Basics



Week	1	2	3	4	5
Dates	8/10- 8/31	9/7- 9/28	10/5- 10/26	11/2-11/23	11/30-12/21
Topic	Systems 1: Intro & Clinical Efficiency	Systems 2: Microsystems & Tools for Improvement	Systems 3: Macrosystems & SDoH	Value-Based Care (+30 min)	Data Science (+30 min)



Week	6	7	8	9	10	11
Dates	1/11-2/1	2/8-3/1	3/8-3/29	4/5-4/26	5/3-5/24	5/31-6/21
Topic	Diagnostic Errors (+60 min)	Systems Errors (RCA) (+60 min)	Teamwork Simulation (+60 min)	Error Disclosure & Second Victim (+60 min)	Narrative Medicine (+60 min)	Present HSPs!



Health System Projects Will Be Completed Across Weeks 4-11




Today's Agenda

- Recap week 5
- **System vs cognitive errors**
- Cognitive bias
- Wrap up
- HSPs

ERRORS

System Errors: Imperfect delivery of a well-chosen care plan




No Fault Errors: Atypical presentations or outside the bounds of our collective medical knowledge

Cognitive Errors: Thinking flaws that lead to an error in diagnosis or treatment plan



Figure 1. Factors Contributing to Diagnostic Error in 100 Patients



Source: Graber ML, Franklin N, Gordon R. Diagnostic error in internal medicine. Arch Intern Med. 2005;165(13):1493-1499.

Diagnostic error in medicine: analysis of 583 physician-reported errors

Comparative Study > Arch Intern Med. 2009 Nov 9;169(20):1881-7.

Types of Errors

- 44% Occur in testing phase
- 32% Clinician assessment
- 10% History taking
- 10% Physical examination
- 3% Referral or consultation errors and delays

Cognitive diagnostic error in internal medicine

Kees van den Berge^a   Silvia Mamede^{a, b}

European Journal of Internal Medicine

Volume 24, Issue 6, September 2013, Pages 525-529

Scope of diagnostic errors

- Up to 98,000 Americans die annually as a result of medical errors and cost between \$17-29 billion annually

Sources of error

- 100 cases of diagnostic error reviewed, typically involved system-related (65%) and cognitive factors (74%)

How can we do better

- Reflective reasoning may counteract bias and seems to improve diagnostic accuracy in complex cases



Today's Agenda

- Recap week 5
- System vs cognitive errors
- **Cognitive bias**
- Wrap up
- HSPs

DISCLAIMER

- We use case examples for each cognitive bias.
- They are resident cases because they are relatable to you as trainees, and available to us as academic attendings.
- They are **NOT** meant to point blame.
- **Every one of us** has made several diagnostic errors at every stage of our careers (including as attendings).

Confirmation Bias



Cognitive Bias

Bias	Definition
Confirmation	
Authority	
Anchoring	
Availability	

Case: 90 y/o man with HFpEF, COPD on 2L home O2, Afib on warfarin, HTN, and TR who presented to night float c/o SOB. He is a poor historian and hard of hearing. He says he has been feeling SOB for months but worse in the past few days. Feels like he can't move without getting very SOB. He has kyphosis and always uses several pillows. He takes torsemide 80mg daily which was increased from 40mg daily 2 weeks ago and 20 mg daily 2 months ago. He doesn't regularly check his weight. He has been coughing more recently with whitish sputum.

Exam:

Gen: Elderly, frail man laying in bed

JVP: Upper 1/3 of neck

Cardiac: Irregularly irregular, soft SEM heard best at base

Lungs: Few scattered rhonchi, poor air movement

Abd: Soft, NTND

Extremities: 1+ edema to his ankles

Labs: Creatinine 2.5 (baseline 1.9), BUN 50 (baseline 30), K 3.3, Na 146

What do you suspect is going on?

Course Update:

- Night float starts him on 100mg IV Lasix for CHF exacerbation & 40mg prednisone for COPD exacerbation. Morning labs are similar to admission labs.
- Resident in the morning presents patient to the attending as a CHF exacerbation +/- maybe a soft call on a COPD exacerbation. Their plan is another 100mg IV Lasix.
- Attending sees the patient, cancels Lasix, orders a Cardiology consult for **unstable angina**.

Question: What happened?

Provoking Situations & Factors for Confirmation Bias

- Pre-drawn conclusions based on sign out
- Lack of differential diagnosis
- Assuming the first diagnosis is the correct one

WHY??

Mitigating Factors for Confirmation Bias

- Explore facts that don't fit into the picture
- Look for items that refute not just confirm a diagnosis
- Make your own differential diagnosis
- Use a diagnostic checklist and see if anything doesn't match

Dynamed Admission Checklist

The screenshot displays the Dynamed website interface. At the top, there is a dark blue header with the Dynamed logo on the left, a user profile icon and 'PORTLAND VA MEDICAL CENTER SIGN IN' text in the center, and a 'Learn more about CME' button on the right. Below the header, the page title 'Cellulitis' is shown in a light blue bar. A breadcrumb trail reads 'Hospitalist Focused Content > Admission Checklists > Admission Checklist for Patients With Cellulitis'. A left-hand navigation menu lists various topics, with 'Admission Checklist for Patients With Cellulitis' highlighted in bold. The main content area is titled 'Admission Checklist for Patients With Cellulitis' and contains a bulleted list of clinical points.

Cellulitis

Hospitalist Focused Content > Admission Checklists > Admission Checklist for Patients With Cellulitis

- > Overview and Recommendations
- Related Summaries
- > Hospitalist Focused Content
 - > Admission Checklists
 - General Admission Checklist
 - Admission Checklist for Patients With Cellulitis**
 - Treatment Setting
 - Consultation and Referral
 - Discharge Planning
 - Discharge Checklist
 - > General Information
 - > Epidemiology
 - > Etiology and Pathogenesis
 - > History and Physical
 - > Diagnosis

Admission Checklist for Patients With Cellulitis

- * Look for potential portals of entry such as: ¹
 - Intravenous lines
 - Tinea pedis
 - Intertrigo
 - Scratches
 - Insect bites
 - Ulcer
 - Recent surgery
- * Assess for conditions associated with complication such as: ¹
 - Diabetes mellitus
 - Cirrhosis
 - Neutropenia
 - Peripheral vascular disease
 - Lymphedema
 - Immunosuppression
 - Prior skin abscesses
- Ask about environmental exposures which may lead to atypical organisms such as animal bites, human bites, marine exposures, and hot tub exposure ¹
- Ask about substance abuse including IV drug use and subcutaneous injection of drugs (skin popping)^{Consensus}

Access Medicine - DDX Tool

The screenshot displays the Access Medicine website interface. At the top, there is a navigation bar with links for "Previous", "Next", and "Options". Below this, the browser address bar shows the URL "ical-com.liboff.ohsu.edu/". The main header features the "ACCESS Medicine" logo and a navigation menu with categories: "Books", "Quick Reference", "Drugs", "Multimedia", "Cases", "Study Tools", "Patient Ed", and "Hospital Corner". A search bar is located below the navigation menu, with the text "AccessMedicine" and "Search AccessMedicine".


A dropdown menu is open, showing the following options:

- Access Provided by: Oregon Health & Science University
- Sign in or Create a Free MyAccess Profile
- Sign Out

The "Sign in or Create a Free MyAccess Profile" option is highlighted with a red rectangular box. Below the navigation menu, there is a row of book covers including "HARRISON'S PRINCIPLES OF INTERNAL MEDICINE", "CURRENT Medical Diagnosis & Treatment 2020", "Goodman & Gilman's THE PHARMACOLOGICAL BASIS OF THERAPEUTICS", "FITZPATRICK'S DERMATOLOGY 10TH EDITION", "POCKET GUIDE TO POCUS", and "CURRENT Practice Guidelines in Primary Care 2019".

At the bottom of the page, there are three featured sections: "AccessMedicine Channel" with the text "Why is everyone searching...", "Harrison's Channel" with the text "20th Edition HARRISON'S PRINCIPLES OF INTERNAL MEDICINE", and "Case of the Week" with the text "Curriculum".

Access Medicine - DDX Tool



Similar to UpToDate
(ie, general information search)

Ddx generator

Basic training and information
on diagnostic testing

Authority Bias



Cognitive Bias

Bias	Definition
Confirmation	Tendency to seek/focus on data to confirm, not refute, the hypothesis
Authority	
Anchoring	
Availability	

Case: 66 y/o woman w/tonsillar SCC on palliative chemotherapy with newly diagnosed mets to her left lung presents with cough, SOB and fever concerning for post-obstructive PNA. Bronchoscopy performed on hospital day 1 (HD1) showed exophytic infiltration into the L bronchus and distal L mainstem. Initially managed on amp/sulbactam, but on HD3 she becomes increasingly hypoxemic and spikes fever to 101.5 and Abx are broadened to Zosyn to include Enterobacter and Pseudomonas. Pt stabilizes and is narrowed to Augmentin on HD5 but spikes a fever that evening to 100.9 and is re-broadened to Zosyn by night team. You pick up the service on HD6.

Exam:

Gen: Elderly, appears old than stated age, breathing comfortably on RA

Cardiac: RRR no murmurs rub or gallops

Lungs: Course breath sounds with rhonchi and crackles in LUL.

Abd: Soft, NT, ND

Labs: WBC is 2.3 (ANC 1000) labs otherwise normal

Imaging: Worsening obstructive change of the left lung, now including portions of the lingula and left upper lobe with marked narrowing of the left mainstem bronchus caused by tumor invasion.

She has felt well for past 2 days despite a single fever on HD5, and she really wants to discharge. She has also been off supplemental oxygen X2 days.

- **Question:** What antibiotic do you cover her with on discharge?

Next Steps: As the resident you are convinced she needs Pseudomonal coverage (the fever spikes when antibiotics were narrowed were not coincidental). You read online and confirm that levofloxacin/ciprofloxacin have good Pseudomonal coverage, but moxifloxacin does *not*. You call the ID attending who says to discharge on Moxifloxacin if you want to cover Pseudomonas and anaerobes with a single drug.

It's time to round and your attending asks your plan... You swallow hard and say moxifloxacin, while cringing to yourself.

Provoking Situations & Factors for Authority Bias

- Rare conditions
- Multiple consultants, attendings, etc.
- Perceived knowledge deficit compared to authority

WHY??

Mitigating Factors for Authority Bias

- Independent or ‘in-parallel’ evaluation
- Face-to-face colloquy with consultants
- “I’m still worried about X, can you walk me through your thinking?”
- Gather your own treatment facts

Tripdatabase.com

Home About How To Use Contact us Blog Tour Latest & greatest Evidence Maps Q&A **NEW!** Sign Up f t G+ Log In

Trip

Find evidence fast

SEARCH PICO **ADVANCED** RECENT

(title:diabetes)(title:aspirin)(heart attack)

8 results for (title:diabetes)(title:aspirin)(heart attack) by quality Alerts Export Snippets

1. The benefits and harms of aspirin for people with type 2 diabetes are finely balanced

as likely to die from **heart** disease or stroke, compared with those without **diabetes**. It's well established that **aspirin** reduces risk in people who have already experienced a **heart attack** or stroke. However, use as primary prevention for people without established disease is debated. A prior study found that **aspirin** may slightly reduce **heart** disease and strokes, but the benefit was outweighed by the bleeding risk. A group of three trials are investigating the use of **aspirin** for primary prevention (...) established that **aspirin** reduces risk in people who have already experienced a **heart attack** or stroke. However, use as primary prevention for people without established disease is debated. A prior study found that **aspirin** may slightly reduce **heart** disease and strokes, but the benefit was outweighed by the bleeding risk. A group of three trials are investigating

2019 NIHR Dissemination Centre

Tweet this Star this Report broken link Key Primary Research

2. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. Full Text available with Trip Pro

Effects of **Aspirin** for Primary Prevention in Persons with **Diabetes** Mellitus. **Diabetes** mellitus is associated with an increased risk of cardiovascular events. **Aspirin** use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovascular events in patients with **diabetes** is unclear. We randomly assigned adults who had **diabetes** but no evident cardiovascular disease to receive **aspirin** at a dose of 100 mg (...) to 1.52; P=0.003), with most of the excess being gastrointestinal bleeding and other extracranial bleeding. There was no significant difference between the **aspirin** group and the placebo group in the incidence of gastrointestinal tract cancer (157 participants [2.0%] and 158 [2.0%], respectively) or all cancers (897 [11.6%] and 887 [11.5%]); long-term follow-up for these

2018 NEJM **Controlled trial quality: predicted high**

Tweet this Star this Report broken link Key Primary Research

3. ASCEND: A Study of Cardiovascular Events in Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation

Evidence type Clinical Area **PRO**

Become a **PRO**

If you had Trip Pro you'd have access to — all without adverts.

Get Trip Pro now >

All Secondary Evidence

Systematic Reviews 0 +0

Evidence-based Synopses 0

Guidelines

Aus & NZ 0

Canada 0

UK 0

USA 0

Other 0

Regulatory Guidance 0
















https://www-unboundmedicine-com.liboff.ohsu.edu/ucentral/index/Davis-Drug-Guide/All_Entries/A


















[SQWM](#) [Vista Phone Book](#) [Remote access req...](#) [AAMC](#) [Employee Travel an...](#) [Concur](#) [BMJ BMJ Formatting yo...](#) [VATAS](#) [Grant Application -...](#)

uCentral



-  Favorites
-  Notes
-  PRIME Publ
-  Bates' Pock Examination
-  Calculators
-  Coronavirus
-  **Davis's Dru**
-  Grasp
-  **Harrison's M**
-  **Johns Hopk**
-  Message C
-  PRIME ForY
-  PRIME Journals

[Home](#) [Favorites](#) [Notes](#) [Prime PubMed](#) **[Mobile](#)** [Grasp](#) [Browse](#) Oregon Health and Science University [Log in](#)

- All Topics 
- Generic Index 
- Brand Index 
- Therapeutic Index 
- Natural and Herbal Index 
- Appendix 
- New FDA Approvals 
- High Alert Index 
- Genetic Index 
- Pharmacological Index 
- Classification Index 
- Combination Index 
- Canadian Index 
- Off Market 
- Medical Safety Tables 
- Frontmatter 
- About Davis's Drug Guide 

Davis's Drug Guide

Stanford Antibigram

Step 2	Organism		Antimicrobial									
Select Organism Groups of Interest (Optional) Select Antimicrobial Subsets, e.g., "Oral Available"	<input type="checkbox"/> Gram Positive <input type="checkbox"/> Gram Positive Cocci in Pairs / Chains <input type="checkbox"/> Gram Positive Cocci in Clusters <input type="checkbox"/> Gram Positive Cocci in Clusters, Coagulase Negative <input type="checkbox"/> Gram Positive Rods <input type="checkbox"/> Gram Negative <input type="checkbox"/> Gram Negative (Diplo)Cocci <input type="checkbox"/> Gram Negative Rods, Lactose Fermenting		<input type="checkbox"/> Gram Negative Rods, Non-Lactose Fermenting <input type="checkbox"/> Gram Negative Rods, Non-Fermenting <input type="checkbox"/> Atypical <input type="checkbox"/> Anaerobe <input type="checkbox"/> Fungal (Yeast) <input type="checkbox"/> Fungal (Mold) <input type="checkbox"/> Fungal (Dimorphic)		<input type="checkbox"/> Oral Available <input type="checkbox"/> Penicillin <input type="checkbox"/> Anti-Staphylococcal Penicillin <input type="checkbox"/> Amino-Penicillin <input type="checkbox"/> Anti-Pseudomonal Penicillin <input type="checkbox"/> Carbapenem <input type="checkbox"/> Monobactam <input type="checkbox"/> Cephalosporin (IV) Gen 1 <input type="checkbox"/> Cephalosporin (IV) Gen 2 <input type="checkbox"/> Cephalosporin (IV) Gen 3+ <input type="checkbox"/> Cephalosporin (PO) Gen 1 <input type="checkbox"/> Cephalosporin (PO) Gen 2 <input type="checkbox"/> Cephalosporin (PO) Gen 3		<input type="checkbox"/> Fluoroquinolone <input type="checkbox"/> Aminoglycoside <input type="checkbox"/> Protein Synthesis Inhibitor <input type="checkbox"/> Macrolide <input type="checkbox"/> Ketolide <input type="checkbox"/> Doxycycline <input type="checkbox"/> Glycylcycline <input type="checkbox"/> Glycopeptide <input type="checkbox"/> Anti-Metabolite <input type="checkbox"/> Urinary Tract <input type="checkbox"/> Miscellaneous <input type="checkbox"/> Anti-Fungal					
	Available		Selected (Clear)		Available		Selected (Clear)					
(Optional) Optimize List of Selected Organisms and Antimicrobials	<div style="border: 1px solid gray; padding: 2px;"> Proteus vulgaris Pseudomonas aeruginosa Pseudomonas aeruginosa CF mucoid Pseudomonas aeruginosa CF non-mucoid Salmonella Serratia marcescens Staphylococcus aureus (MRSA) Staphylococcus aureus (MSSA) Staphylococcus aureus (all) Staphylococcus lugdunensis Staphylococcus Coagulase Negative (spide) </div> <div style="text-align: center; margin-top: 5px;"> <input style="border: 1px solid gray; padding: 2px 10px;" type="button" value="(+)"/> <input style="border: 1px solid gray; padding: 2px 10px;" type="button" value="(-)"/> </div>		<div style="border: 1px solid gray; padding: 2px;"> Pseudomonas aeruginosa </div>		<div style="border: 1px solid gray; padding: 2px;"> Amikacin Amphotericin B Ampicillin-Sulbactam Ampicillin/Amoxicillin Aztreonam Caspofungin Cefazolin Cefepime Ceftazidime Ceftolozane-Tazobactam </div> <div style="text-align: center; margin-top: 5px;"> <input style="border: 1px solid gray; padding: 2px 10px;" type="button" value="(+)"/> <input style="border: 1px solid gray; padding: 2px 10px;" type="button" value="(-)"/> </div>		<div style="border: 1px solid gray; padding: 2px;"> Amikacin Amphotericin B Ampicillin-Sulbactam Ampicillin/Amoxicillin Aztreonam Caspofungin Cefazolin Cefepime Ceftazidime Ceftolozane-Tazobactam </div>					
Step 4 Generate Table	<input type="button" value="Generate Sensitivity Table"/>											
Microbe	Isolates Tested	ALL DRUGS	Amikacin	Aztreonam	Cefepime	Ciprofloxacin	Gentamicin	Imipenem	Levofloxacin	Meropenem	Piperacillin-Tazobactam	Tobramycin
ALL BUGS	580	98	97	86	92	89	91	88	85	91	93	98
Pseudomonas aeruginosa	580	98	97	86	92	89	91	88	85	91	93	98





TALLEST REDWOOD EXERCISE



Cognitive Bias

Bias	Definition
Confirmation	Tendency to seek/focus on data to confirm, not refute, the hypothesis
Authority	Tendency to stop thinking when confronted with authority (a person or an objective test)
Anchoring	
Availability	

Case: 70 y/o man with new Dx of HFrEF <30% (probable NICM) and COPD on 2L home O2 who is transferred from CCU for ongoing management of acute hypoxemic respiratory failure. He was previously at CLC following admitted for ADHF. While on the floor being diuresed, his platelets start to drop over a few days from 190 →70. He is on heparin for DVT prophylaxis.

What do you suspect is going on?

Course Update: The team is not initially sure that HIT is likely, but eventually decides to test for HIT. 2 days later his HIT Ab (ELISA) results positive. He is also transferred to the ICU with sepsis and PNA. He has no clinical signs or symptoms of clotting.

Now what do you suspect is going on?

Question: Since the HIT Ab was positive, it has to be HIT, right? Should heparin be added to his allergy list? Does he need argatroban?

Test Characteristics:

- <0.1% base rate of HIT with heparin Ppx
- 95% sensitivity/specificity for the HIT Elisa

Population: 1000 patients on heparin Ppx

Question: How reliably will HIT Elisa diagnose HIT in this population?

	Have HIT	Don't Have HIT
Test Got it Right	95% (1)= 0.95	95% (999)=949
Test Got it Wrong	5% (1)= 0.05	5% (999)=49

1 TRUE positive

49 False Positives

Test Characteristics:

- 10% base rate of HIT if you have a Warkentin 4Ts = 4
- 95% sensitivity/specificity for the HIT Elisa.

Population: 1000 patients positive 4Ts

Question: How reliably will HIT Elisa diagnose HIT in this population?

	Have HIT	Don't Have HIT
Test Got it Right	95% (100) = 95	95% (900) = 855
Test Got it Wrong	5% (100) = 5	5% (900) = 45

95 TRUE positive

45 False Positives

Provoking Situations & Factors for Anchoring

- Too little understanding of test operating characteristics
- Multiple admissions/visits for a particular problem
- Transfer patients with ‘known’ diagnoses
- “Key words” that trigger tunnel vision

WHY??

Mitigating Factors for Anchoring

- Conscious effort to ask, “What alternatives should be considered?”
- Use a differential tool like “Access Medicine” available at OHSU
- Understand diagnostic test characteristics



Heparin-induced thrombocytopenia

[View PDF](#)

OVERVIEW	THEORY	DIAGNOSIS	MANAGEMENT	FOLLOW UP	RESOURCES
Summary	Epidemiology Etiology Case history	Approach History and exam Investigations Differentials Criteria Screening	Approach Treatment algorithm Emerging Prevention Patient discussions	Monitoring Complications Prognosis	Guidelines Images and videos References Evidence

Investigations

1st investigations to order

[VIEW ALL](#)

CBC

Investigations to consider

[VIEW ALL](#)


Warkentin (4Ts) Probability Scale

TEST	RESULT
<p>The 4Ts score is commonly used to predict the clinical probability of HIT. [35][36] The American Society of Hematology recommends the 4Ts probability scale over other tools. [37]</p> <p>Points from 0-2 are given for 4 categories: magnitude of Thrombocytopenia, Timing of onset of platelet fall (or other sequelae of</p>	<p>score of 6-8 indicates high clinical suspicion for HIT; score of 4-5 indicates intermediate clinical suspicion for HIT; score of 0-3 indicates low clinical suspicion for HIT</p>

Cognitive Bias

Bias	Definition
Confirmation	Tendency to seek/focus on data to confirm, not refute, the hypothesis
Authority	Tendency to stop thinking when confronted with authority (a person or an objective test)
Anchoring	Tendency to lock onto salient features in the initial presentation too early in the diagnostic process and failing to adjust later
Availability	

Availability Bias



Case: 67 y/o M with PMHX of BPH and LBP presents to VA clinic to establish care. During his visit he c/o 2 days of **chest pain.**

Have you ever encountered a patient at the VA where you were concerned about coronary artery disease?

Can someone tell me a brief story about one of their patients from the last 2-3 months? Especially if a diagnosis of CAD/ACS was delayed or missed?

Remember, our brains use a shortcut that if something can be recalled, it must be important. And we are inherently biased towards recently acquired information.

Case: 67 y/o M with PMHX of BPH and LBP presents to VA clinic to establish care. During his visit he c/o 2 days of **chest pain**, without radiation, that is “**sharp and stabby**” but also **burning in nature**. It has been waxing and waning over 2 days, it is not exertional, and started while watching the evening news after a spicy dinner. He notes some *mild nausea* associated. He *has not had a similar pain before and has no history of CAD*. He thinks he is having a heart attack.

Social hx: Never smoker, never drinker, lives with wife, worked as a mail man and just retired 3 months ago

Family hx: No family hx of CAD

Exam:

Vitals: BP 110/70 and *HR 70* without orthostatic changes, afebrile

Gen: Lying in bed in NAD, speaking full sentences, appears fit and healthy

Neck: JVP in clavicular fossa at 90 degrees

Cardiac: **RRR no m/r/g**

Lungs: CTAB

Abd: Soft abdomen, no organomegaly, + BS, **mild TTP in epigastrium**,

Extremities: Trace edema at ankles

Based on the focused information above, what might be going on?

Do you feel reassured, or do you think about your recent patient who had serious CAD?

Initial A/P from clinic:

Chest pain:

- No prior angio/stress test in our system
- EKG in clinic is unremarkable w/o e/o ischemia
- Refer to ED for further work up & admission for ACS work up

ED Course:

-Troponin x2 WNL

-EKG WNL

-CBC, BMP, BNP WNL

-Admitted for a stress test (*you argue to the ED that his HEART score is 2, purely driven by age > 65, so he has a ~1% risk of major adverse cardiac event, and in the HEART Score study this patient would be safe for early discharge.. But you lose.*)

Admission Course:

-CMP ordered shows AST/ALT in 200s, alk phos 215, tbili 5.7

-F/u RUQ US shows biliary dilation

Provoking Factors for Availability Bias

- Recent exposure to a disease (over diagnosis, e.g. CAD at the VA)
- No recent exposure to a disease (under diagnosis)
- Working in niche practices where you see more “zebras”

WHY??


Mitigating Factors for Availability Bias

- Know the predictive value of history & exam findings
- Question if you are seeing too many or too few zebras
- Applying Bayesian reasoning

Understanding the Likelihood Ratio

- Likelihood Ratio tell us...

- How much a test alters our pre-test probability to generate the post-test probability (our updated prediction of likelihood of disease)



$LR+ = \text{sensitivity} / 1 - \text{specificity}$
 $LR- = 1 - \text{sensitivity} / \text{specificity}$

1. Inherent characteristic of the test itself
2. Does not change with population prevalence

Positive Findings (Patient Has This)

Cardiac Risk	Increased Disease Probability (Positive Likelihood Ratio)
Abnormal prior stress test	3.1x (2.0-4.7)
Peripheral arterial disease	2.7x (1.5-4.8)
Prior history of CAD	2.0x (1.4-2.6)
Prior MI	1.6x (1.4-1.7)
Diabetes	1.4x (1.3-1.6)
CVA	1.4x (1.1-1.8)
Male gender	1.3x (1.2-1.3)
Hyperlipidemia	1.3x (1.1-1.5)
Hypertension	1.2x (1.1-1.3)
Any tobacco use	1.1x (0.9-1.3)
Family history of CAD	1.0x (0.9-1.2)
Obesity	1.0x (0.9-1.2)
History of CABG	0.97x (0.5-2.1)
Chest pain characteristics	Increased Disease Probability (Positive Likelihood Ratio)
Radiation to both arms	2.6x (1.8-3.7)
Pain similar to prior ischemia	2.2x (2.0-2.6)
Change in pattern over prior 24 hours	2.0x (1.6-2.5)

RELATED REVIEWS

[Other Cardiac Diagnostics](#)
[Cardiac Interventions](#)

OTHER EBM RESOURCES

[MDCalc](#)
[BMJ Evidence Updates](#)
[JAMA Evidence - The Rational Clinical Exam Series](#)


A relatively high likelihood ratio of **10** or greater will result in a large and significant increase in the probability of a disease, given a positive test.

A LR of **5** will moderately increase the probability of a disease, given a positive test.

A LR of **2** only increases the probability a *small amount*.

A relatively low likelihood ratio (0.1) will significantly decrease the probability of a disease, given a negative test.

A LR of 1.0 means that the test is not capable of changing the post-test probability either up or down and so the test is not worth doing!



This is only true between 10-90% if you fall into the extreme of <10% of >90% this scale becomes inaccurate

Aspirin For Preventing A First Heart Attack Or Stroke

No overall benefit for primary prevention.

In summary, for patients who received aspirin:

Benefits in NNT

- No deaths were prevented
- 1 in 333 avoided a nonfatal heart attack
- Unclear if ischemic strokes avoided

Harms in NNT

1 in 250 suffered a major bleeding event

View As: **NNT** %

Details for this Review

Further References

Source: [Bibbins-Domingo K. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventative Service Task Force Recommendation Statement. Ann Intern Med. 2016;164:836-845.](#)

[Mahmoud AN, Gad MM, Elgendy AY, Elgendy IY, Bavry AA. Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials. Eur Heart J. 2019;40:607-17.](#)

[Zheng SL, Roddick AJ. Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis. JAMA. 2019;321:277-87.](#)

Study Population: Approximately 164,000 subjects at varying risk for cardiovascular disease.

Efficacy Endpoints: Death, heart attack, stroke, measured over 5-7 years.

Harm Endpoints: Major bleeding events, hemorrhagic strokes.

Narrative: Cardiovascular disease (CVD) is a major cause of death worldwide. Aspirin inhibits platelet aggregation which reduces clot

RELATED REVIEWS

[Cardiac Interventions That Do Work](#)

[Cardiac Interventions That Don't Work](#)

[Cardiac Interventions That Need More Study](#)

INTERACT

[Share on Facebook](#)

[Share on Twitter](#)

[Send Us Feedback on This Review](#)

OTHER EBM RESOURCES

[MDCalc](#)

[Trip Database](#)

[BMJ Evidence Updates](#)

[JAMAEvidence - The Rational Clinical Exam Series](#)




Today's Agenda


- Recap week 5
- System vs cognitive errors
- Cognitive bias
- **Wrap up**
- HSPs

Tools


DDx Generator



Admission Checklist





Antibiotics



...ants &
...s who
look over for patient care


- What did they do different?

PICO Question



NNT & LR

Diagnostic Tests



FEEDBACK



bit.ly/WiscWK7FB

(case sensitive)






Today's Agenda

- Recap week 5
- Systems vs cognitive errors
- Cognitive bias
- Wrap up
- **HSPs**

Health System Project (HSP) Timeline:

11/2-11/23	11/30-12/21	1/11-2/1	2/8-3/1	3/8-3/29	4/5-4/26	5/3-5/24	5/31-6/21
Introduction to HSPs	Team & project selection, planning	Background & current state	Targets & metrics	Fishbone & root cause statements	Develop counter-measures	Finalizing PPT	Presentations! 

MODIFIED A3

Background:

Root Causes:

Develop Countermeasures:

Implement Countermeasures (PDSA):

Current State:

Targets & Metrics:

Follow Up Plan:

Background Investigation


1. Is this a problem reported elsewhere?
2. How have others have solved this problem?
3. Is there alignment with local quality priorities?

Current State

1. Is there a problem?
 - Prove this with baseline data whenever possible
2. Characterize the problem
 - Interviews
 - Chart review
 - Data pull

Peer Learning

- Same groups every month
- Update: 3-5 minutes per team to describe the state of your project
- Next Steps: 5-7 minutes for group brainstorming of next steps



Peer Learning:

Background & Current State

- **Update: Describe your project–**
 - Topic of your project
 - Who is your Mentor
 - Location (inpatient/outpatient/specialty etc.)
- **Next Steps–**
 - Background: Is anyone aware of literature, institutional priorities or groups working on this?
 - Current State:
 - Who should we talk to?
 - Is there data we should collect?
 - What other points of view might be valuable?